摘要(中文译文)
※ 中文译文由 AI 辅助生成,仅供学术参考,请以英文原文为准。
动脉粥样硬化性心血管疾病（ASCVD）尽管在危险因素控制和降脂治疗方面取得了重大进展，但仍然是全球发病和死亡的主要原因。炎症是动脉粥样硬化的核心驱动因素，参与疾病的发生、进展和额外心血管风险。本文总结了动脉粥样硬化的病理生理学，重点阐述了斑块形成和不稳定性背后的炎症机制、抗炎治疗策略，以及固有免疫细胞的表观遗传和代谢编程在维持未消退炎症中的新兴作用。
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality worldwide despite major advances in risk factor attenuation and lipid-lowering therapies. Inflammation is a central driver of atherosclerosis, contributing to disease initiation, progression, and excess cardiovascular risk. This article summarizes the pathophysiology of atherosclerosis with a focus on the inflammatory mechanisms underlying plaque development and instability, anti-inflammatory therapeutic strategies, and the emerging role of epigenetic and metabolic programming of innate immune cells in perpetuating unresolved inflammation.
如何引用
AMA
Ilana S Nazari, Samuel A McFarlane, Meena S Madhur, Allison E Norlander, Edward B Thorp, Matthew J Feinstein. Emerging evidence of trained immunity and inflammatory programming in atherosclerotic cardiovascular disease.. Canadian journal of physiology and pharmacology. 2026; doi:10.1139/cjpp-2026-0149.
APA
Ilana S Nazari, Samuel A McFarlane, Meena S Madhur, Allison E Norlander, Edward B Thorp, Matthew J Feinstein (2026). Emerging evidence of trained immunity and inflammatory programming in atherosclerotic cardiovascular disease.. Canadian journal of physiology and pharmacology. https://doi.org/10.1139/cjpp-2026-0149
GB/T 7714
Ilana S Nazari, Samuel A McFarlane, Meena S Madhur, Allison E Norlander, Edward B Thorp, Matthew J Feinstein. Emerging evidence of trained immunity and inflammatory programming in atherosclerotic cardiovascular disease.[J]. Canadian journal of physiology and pharmacology, 2026 doi:10.1139/cjpp-2026-0149.
在 PubMed中文版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出